What valuation the new company can achieve will be based on the financials when they come out as a public reporting company. What we know of that business is that is growing, global and seems well run. The best way to value the company is buy looking at comparable stem cell companies. Always keep an eye on outstanding share count -- and as always do your own review of the facts.